FDA approves XNPT Horizant. OREX initiates cardio outcomes trial. AIS to transfer to NASDAQ. ACHN CMO resigns + NBY news

Jun 07, 2012 No Comments by

GlaxoSmithKline plc (GSK) and XenoPort, Inc. (Nasdaq:XNPT) announced the FDA approved their supplemental new drug application of Horizant for the management of postherpetic neuralgia (PHN) in adults.

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that it has initiated its cardiovascular outcomes trial, called the Light-Study,  evaluating the occurrence of major adverse cardiovascular events (MACE) in patients taking Contrave, for the treatment of obesity. An interim analysis and NDA submission is planned once 87 MACE events have occurred, which is expected to be by mid-2014.

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced the resignation of Elizabeth A. Olek, D.O., Senior Vice President of Clinical Development and Chief Medical Officer, effective June 18, 2012.

NovaBay Pharmaceuticals, Inc. (NYSE AMEX: NBY) said that it expects to initiate a global Phase 2b trial of  NVC-422 for treating impetigo, during 3Q 2012.

Antares Pharma, Inc. (NYSE Amex: AIS) announced that it will transfer from the NYSE Amex Exchange to the NASDAQ Capital Market on June 15, 2012 under the ticker symbol “ATRS.”

 

 

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “FDA approves XNPT Horizant. OREX initiates cardio outcomes trial. AIS to transfer to NASDAQ. ACHN CMO resigns + NBY news”

Leave a Reply